CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel combination therapy for triple negative breast cancer by targeting specific signaling pathways. It explores the use of a cyclin-dependent kinase 9 inhibitor alongside epidermal growth factor receptor targeting to improve treatment outcomes.
Triple negative breast cancer (TNBC) is an aggressive disease, accounting for 15-20% of breast cancer cases, but disproportionally causing breast cancer-related death. TNBC does not express the targetable receptors ER, PR, and HER2 that are known to drive other forms of breast cancer.
Mainstay practice for TNBC in the clinic is to treat with non-targeted cytotoxic chemotherapies.
Long-term outcomes are however still poor, most likely owing to intrinsic drug resistance.
Clinical trials have attem…
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
